title: [Pantogam augmentation in hyperkinetic behavior disorder treatment].
abstract: A clinical case of a child with hyperkinetic conduct disorder is presented, with symptoms of hyperkinetic disorder itself closely intertwining with symptoms of conduct disorder. The qualitative changes in the child's condition are noted, including not only achieved control over the symptoms, but also improved social functioning level, achieved by means of Pantogam (neuroprotective drug) addition to atomoxetine therapy. The proposed strategy can contribute to improvement of treatment results for children with certain clinical types of hyperkinetic conduct disorder.
authors.affiliation: Moscow Research Institute of Psychiatry, of Federal Medical Research Center of Psychiatry and Narcology, Moscow, Russia.
authors.forename: T A
authors.initials: TA
authors.lastname: Kupriyanova
authors.affiliation: Moscow Research Institute of Psychiatry, of Federal Medical Research Center of Psychiatry and Narcology, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Koren
mesh_terms: D000069445:Atomoxetine Hydrochloride / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D019955:Conduct Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy; D008297:Male; D018697:Nootropic Agents / Q000627:therapeutic use*; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D018697:Nootropic Agents; C016030:pantogab; D010205:Pantothenic Acid; D005680:gamma-Aminobutyric Acid; D000069445:Atomoxetine Hydrochloride